Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 11/20 | 0.47 |
| ▸ | CACNB1 | Q02641 | 11/20 | 0.47 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 10/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 9/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.46 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14459925 | 0.85 | CACNA2D1 (0.51) | CACNA2D1CACNB1CACNA1ACACNA1CMEN1 | |
| SCHEMBL5635007 | 0.82 | CACNA2D1 (0.45) | CACNA2D1CACNB1CACNA1ACACNA1CMEN1 | |
| SCHEMBL14459927 | 0.81 | CACNA2D1 (0.46) | CACNA2D1CACNB1CACNA1ACACNA1CMEN1 | |
| SCHEMBL14459926 | 0.81 | DPP4 (0.48) | MEN1ALDH1A1POLBKMT2ASLC6A9 | |
| SCHEMBL4460130 | 0.81 | CCR5 (0.58) | CACNA2D1CACNB1CACNA1ACACNA1CMEN1 | |
| SCHEMBL4473810 | 0.81 | CCR5 (0.58) | CACNA2D1CACNB1CACNA1ACACNA1CMEN1 | |
| SCHEMBL4460125 | 0.81 | CCR5 (0.58) | CACNA2D1CACNB1CACNA1ACACNA1CMEN1 | |
| SCHEMBL5633504 | 0.81 | SLC6A9 (0.43) | CACNA2D1CACNB1CACNA1ACACNA1CMEN1 | |
| SCHEMBL14476477 | 0.80 | SLC6A9 (0.42) | CACNA2D1CACNB1CACNA1ACACNA1CMEN1 | |
| SCHEMBL5634347 | 0.78 | CACNA2D1 (0.54) | CACNA2D1CACNB1CACNA1ACACNA1CMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244758-B2 | N-type calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-07-17 | — | — | US | claimed |
| JP-2006526000-A | — | — | 2006-11-16 | — | — | JP | claimed |
| CN-1816332-A | 3-aminomethyl-pyrrolidines as N-type calcium channel blockers | NEUROMED TECH INC (CA) | 2006-08-09 | — | — | CN | claimed |
| EP-1633343-A1 | 3-AMINOMETHYL-PYRROLIDINES AS N-TYPE CALCIUM CHANNEL BLOCKERS | Neuromed Technologies, Inc. (CA) | 2006-03-15 | — | — | EP | claimed |
| US-20050014748-A1 | N-type calcium channel blockers | NEUROMED TECHNOLOGIES INC. | 2005-01-20 | — | — | US | claimed |
| WO-2004105750-A1 | 3-AMINOMETHYL-PYRROLIDINES AS N-TYPE CALCIUM CHANNEL BLOCKERS | NEUROMED TECHNOLOGIES, INC. (CA) | 2004-12-09 | — | — | WO | claimed |
| US-7244758-B2 | N-type calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-07-17 | — | — | US | disclosed |
| US-7244758-B2 | N-type calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-07-17 | — | — | US | disclosed |
| US-7244758-B2 | N-type calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-07-17 | — | — | US | disclosed |
| CN-1816332-A | 3-aminomethyl-pyrrolidines as N-type calcium channel blockers | NEUROMED TECH INC (CA) | 2006-08-09 | — | — | CN | disclosed |
| US-20050014748-A1 | N-type calcium channel blockers | NEUROMED TECHNOLOGIES INC. | 2005-01-20 | — | — | US | disclosed |
| WO-2004105750-A1 | 3-AMINOMETHYL-PYRROLIDINES AS N-TYPE CALCIUM CHANNEL BLOCKERS | NEUROMED TECHNOLOGIES, INC. (CA) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014748-A1 | N-type calcium channel blockers | CACNA1B, CACNA1C, CACNA1I | CACNA2D1 30/4885CACNB1 13/4885CACNA1A 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.